Solid tumors, due to their biological complexity, present significant treatment challenges. The OSF Breakthrough Treatment Center, in collaboration with global partners, is conducting research to explore innovative approaches that may improve patient outcomes.

One such area of study involves C’Dot-Drug-Conjugates (CDCs), investigational drug delivery systems designed to penetrate tumors more effectively and deliver higher therapeutic payloads. These systems are being evaluated for their potential to improve treatment efficacy across a broader range of tumors while minimizing off-target toxicity.

This research is part of OSF’s commitment to advancing the understanding and treatment of solid tumors through rigorous study and collaboration. The findings from these studies could help address key limitations of existing therapies and inform future treatment strategies.